Core Viewpoints - The company announced that its LinX continuous glucose monitoring (CGM) system has recently received market approval in Brazil, further strengthening its international expansion strategy [1] - The CGM product is expected to continue its growth trend in the domestic market through both online and offline channels, while overseas markets show significant potential for revenue growth due to a low revenue base and increasing market share [1][3] - The company reported a net loss of only 2.29 million yuan in the first half of 2025, nearing breakeven, with expectations of achieving profitability by 2026 [1][3] Event Summary - On December 23, 2025, the company announced that its LinX CGM system received market approval in Brazil for both adults and children, enhancing its market presence in Latin America [1] Market Performance - The company reported a 218% increase in GMV during the "Double Eleven" shopping festival, with the second-generation CGM device's shipment volume increasing by 622.8% and new user numbers rising by 300% [2] - The company ranked first in sales on major e-commerce platforms, indicating effective brand promotion [2] R&D Progress - The company is making steady progress in its R&D pipeline, with clinical trials for the AiDEX CGM system for pregnant women completed and the Equil insulin pump system's clinical trial enrollment in Europe finished [2] - The company is exploring AI applications in CGM through internal team formation and collaborations with leading research institutions, aiming to innovate diabetes management [2] Revenue and Profit Outlook - The company expects continued high revenue growth in 2026, with a projected revenue of 5.31 billion yuan in 2025, representing a year-on-year growth of 53.78% [3] - The company anticipates achieving breakeven in 2025 and profitability in 2026, supported by stable gross margins and cost optimization measures [3]

公司近日发布公告称，其LinX持续葡萄糖监测系统已获得巴西的上市批准，适用于成人及儿童的连续 动态血糖监测。公告指出，巴西是拉丁美洲的核心市场，根据国际糖尿病联盟《2025全球糖尿病地图》 数据，巴西20–79岁糖尿病患者约1,662万人，患病率达10.7%，患病人数居全球第六；2024年糖尿病相 关支出达约451亿美元，位居全球第三。此次获批将有助于公司进一步拓展拉丁美洲市场，推动国际业 务的规模化扩张与收入增长。公司表示将继续聚焦糖尿病监测、治疗及管理领域的技术创新与全球发 展。董事会提醒投资者，产品生产、销售及收益受市场变化等因素影响，股东及潜在投资者应审慎行 事。 最新公告列表 《自愿性公告 本公司持续葡萄糖监测系统海外获批》 截至2025年12月24日收盘，微泰医疗-B（02235）报收于7.68元，较前一交易日上涨0.52%。该股当日开 盘价为0.0元，最高价0.0元，最低价0.0元，成交额为0元。近52周最高价为9.17元，最低价为4.0元。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Group 1: Copper Price Surge - Copper prices have reached a historic high, surpassing $12,000 per ton, driven by significant mine shutdowns and trade disruptions caused by U.S. tariffs [1] - The London Metal Exchange's copper futures peaked at $12,044 per ton, reflecting a cumulative increase of approximately 37% this year [1] - The potential imposition of tariffs on copper by President Trump has been a key factor in driving prices up, with U.S. imports rising sharply [1] Group 2: Supply Chain Disruptions - Severe disruptions in the supply chain due to mine shutdowns across the Americas, Africa, and Asia are raising concerns about a significant copper market deficit [1] - Deutsche Bank has warned that the production of the world's largest mining companies is expected to decline by 3% this year, with further declines anticipated by 2026 [1] Group 3: Precious Metals Market - The bull market for precious metals continues, with gold, silver, copper, and platinum all reaching new highs [2] - COMEX gold futures rose by $45.60, or 1.02%, to $4,515.0 per ounce, while COMEX silver futures increased by $3.045, or 4.44%, to $71.61 per ounce [2]

格隆汇12月23日丨微泰医疗-B(02235.HK)宣布，公司的LinX持续葡萄糖监测系统，近期获得巴西的上市 批准，适用于成人及儿童的连续动态血糖监测。 巴西作为拉丁美洲的核心市场，具备巨大的市场潜力，根据国际糖尿病联盟(IDF)《2025全球糖尿病地 图》数据，巴西20–79岁糖尿病患者约1,662万人，患病率达10.7%，患病人数位列全球第六；2024年巴 西糖尿病相关支出达约451亿美元，位列全球第三，仅次于美国和中国。 公司LinX持续葡萄糖监测系统在巴西获批上市，将极大强化公司在拉丁美洲的市场布局，为国际业务 的规模化扩张与收入增长奠定坚实基础。未来，公司将继续聚焦糖尿病监测、治疗及管理方式的全球发 展，持续推动相关领域技术与产品创新。 ...

智通财经APP讯，微泰医疗-B(02235)公布，集团的的LinX持续葡萄糖监测系统，近期获得巴西的上市 批准，适用于成人及儿童的连续动态血糖监测。 公司LinX持续葡萄糖监测系统在巴西获批上市，将极大强化公司在拉丁美洲的市场布局，为国际业务 的规模化扩张与收入增长奠定坚实基础。未来，公司将继续聚焦糖尿病监测、治疗及管理方式的全球发 展，持续推动相关领域技术与产品创新。 ...

公司LinX持续葡萄糖监测系统在巴西获批上市，将极大强化公司在拉丁美洲的市场布局，为国际业务 的规模化扩张与收入增长奠定坚实基础。未来，公司将继续聚焦糖尿病监测、治疗及管理方式的全球发 展，持续推动相关领域技术与产品创新。 微泰医疗-B(02235)公布，集团的的LinX持续葡萄糖监测系统，近期获得巴西的上市批准，适用于成人 及儿童的连续动态血糖监测。 ...

Core Insights - The current dynamic continuous glucose monitoring (CGM) market is experiencing a "price war," prompting Chinese manufacturers to target overseas markets to capture a share of the global multi-billion dollar market [1][2] - Chinese CGM companies such as Weitai Medical, Sanofi Biologics, and others are expanding into regions like India, Southeast Asia, and Europe, previously dominated by international giants [1][2][3] Market Expansion - Chinese CGM manufacturers are focusing on emerging markets like Indonesia and Algeria, where there is a growing demand for medical devices and relatively flexible market entry requirements [2][3] - Weitai Medical has recently received approval for its LinX CGM system in India, which has a significant diabetic population of nearly 90 million [1][2] - Sanofi Biologics has reported explosive growth in Indonesia, attributing this to a local team and tailored products [2][3] Regulatory Landscape - The European market is seen as a "test stone" for CGM companies due to its high regulatory standards and established healthcare systems [3] - Several Chinese CGM products have obtained EU CE certification, facilitating easier entry into other markets [3] Technological Advancements - Chinese CGM manufacturers are shifting from a "Made in China" image to a "Smart Manufacturing" approach, focusing on improving product accuracy and user experience [4][5] - The average absolute relative difference (MARD) value, a key performance indicator for CGM accuracy, has improved significantly, with leading brands now achieving values below 10% [5] Future Directions - The competition in the CGM market is expected to evolve beyond hardware specifications to include comprehensive diabetes management solutions [6][7] - The integration of advanced technologies, such as iCGM systems and artificial pancreas concepts, represents the future direction of diabetes management [7] Challenges and Considerations - Intellectual property issues pose significant challenges for Chinese CGM companies entering the global market, with patent litigation being a common concern in the US and Europe [8] - The global blood glucose monitoring market is valued at over $30 billion, and Chinese companies must enhance their technological capabilities and brand recognition to compete effectively [8] Strategic Outlook - The year 2026 is projected to be a critical juncture for Chinese CGM companies, influenced by FDA registration progress, EU healthcare access, and local production initiatives in emerging markets [8]

Core Viewpoint - 微泰医疗-B's LinX continuous glucose monitoring system has received market approval in India, marking a significant entry into a high-growth market with substantial diabetes management needs [1] Company Summary - The LinX system is recognized for its superior performance and reliability, having been integrated into healthcare systems across multiple European countries and gaining access in emerging markets in the Middle East, Asia-Pacific, and South America [1] - The approval in India is expected to greatly expand the company's international market reach, laying a solid foundation for scaling international operations and revenue growth [1] Industry Summary - The global continuous glucose monitoring market is experiencing strong growth, with India representing a core emerging market with vast potential [1] - According to the IDF's 2025 Global Diabetes Map, there are approximately 89.83 million diabetes patients aged 20-79 in India, with a prevalence rate of 9.5%, ranking second globally [1] - The rising prevalence of prediabetes and the trend of younger patients indicate a significant gap in diabetes management systems, creating urgent demand for digital and intelligent diabetes management solutions [1] - The company's focus on global development in diabetes monitoring, treatment, and management will continue to drive innovation in related technologies and products [1]

Core Viewpoint - The company, MicroTech Medical-B (02235), has received approval for its LinX continuous glucose monitoring system in India, marking a significant entry into a high-growth market with substantial diabetes prevalence [1][2]. Group 1: Product Approval and Market Entry - The LinX system has been approved for continuous glucose monitoring in adults in India, enhancing the company's international market presence [1]. - The system has already been integrated into healthcare systems across multiple European countries and has gained access in emerging markets in the Middle East, Asia-Pacific, and South America [1]. Group 2: Market Potential and Demand - India has approximately 89.83 million diabetes patients aged 20-79, with a prevalence rate of 9.5%, ranking second globally in terms of patient numbers [1]. - The country also faces a significant increase in prediabetes rates and a concerning trend of younger individuals being affected, indicating a substantial demand for digital and intelligent diabetes management solutions [1]. Group 3: Future Focus - The company plans to continue focusing on the global development of diabetes monitoring, treatment, and management, while driving innovation in related technologies and products [2].

Core Viewpoint - The company has received approval for its LinX continuous glucose monitoring system in India, marking a significant entry into a high-growth market with substantial diabetes prevalence [1]. Group 1: Product Approval and Market Entry - The LinX system has been approved for continuous glucose monitoring in adults in India, enhancing the company's international market presence [1]. - The system has already been integrated into healthcare systems across multiple European countries and has gained access in emerging markets in the Middle East, Asia-Pacific, and South America [1]. Group 2: Market Potential and Demand - India has approximately 89.83 million diabetes patients aged 20-79, with a prevalence rate of 9.5%, ranking second globally [1]. - The country also has the highest number of diabetes-related deaths, indicating a critical need for effective diabetes management solutions [1]. - The rising prevalence of prediabetes and the trend of younger patients highlight a significant gap in the current healthcare system, creating urgent demand for digital and intelligent diabetes management solutions [1]. Group 3: Future Focus - The company plans to continue focusing on the global development of diabetes monitoring, treatment, and management, driving innovation in related technologies and products [2].